Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

YEAR-END REPORT 2020

Summary Q4Financial overview October 1 – December 31, 2020 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 513.0 M (loss: 244.9) · Loss per share, before and after dilution, was SEK 7.59 (loss: 4.42) · On December 31 cash and cash equivalents amounted to SEK 840.3 M (926.2) Significant events during the period October 1 – December 31, 2020 · First patient enrolled in the phase 3 LIGHTHOUSE combination study in multiple myeloma · Phase 2 ANCHOR data presented at ASH · Oncopeptides announced the intention to apply for conditional marketing

Sobi publishes report for the fourth quarter and full-year 2020

Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces its results for the fourth quarter and full-year 2020. Revenue growth for the full-year was 7 per cent with revenue of SEK 15,261 M. Adjusted EBITA was SEK 6,301 M, resulting in an adjusted EBITA margin of 41 per cent for the full year. October – December · Total revenue of SEK 4,581 M (4,890), -6 per cent (-2 per cent at CER) · Adjusted EBITA[1,2  ]was SEK 2,177 M (2,380), with an adjusted EBITA margin[1,2 ]of 48 per cent (49). Adjusted EBITA excludes positive impact from reversal of the CVR

Navamedic ASA: Q4 2020 financial results

Oslo, 18 February 2021 – Navamedic ASA (OSE: NAVA) grew revenues by 17% in the fourth quarter of 2020 compared to the same quarter last year. The company reported revenues of NOK 55.3 million in the fourth quarter of 2020 with an EBITDA of negative NOK 3.7 million driven by both new product launches and investments in further growth initiatives. The company reiterates its mid- to long-term ambition of building a NOK 500 million company.“The fourth quarter of 2020 displayed strong growth in our underlying portfolio and new products introduced during the second half of the year. Key growth

Themvar Eight divests its shareholding in Scandi Standard following an accelerated book building process

Scandi Standard’s second largest shareholder Themvar Eight Unlimited Company has informed that it has divested its 6 million shares in Scandi Standard following an accelerated book building process at a price of SEK 60.50 per share.Through an accelerated book building process on 17 February 2021, Themvar Eight Unlimited Company (“Themvar Eight”) divested 6 million shares in Scandi Standard at SEK 60.50 per share, representing a discount of approx. 6% to the closing price the same day. Themvar Eight acquired 6 million shares in Scandi Standard in 2017 as part of the consideration when

Optomed Plc Financial statements bulletin January - December 2020

Optomed Plc         Stock Exchange Release    18 Febryary 2021 at 9:00, Helsinki   Optomed Plc: Financial Statements Bulletin, January – December 2020 October – December 2020 ·Revenue decreased by 6.6 percent to EUR 4,041 (4,329) thousand · Adjusted EBITDA amounted to EUR -62 (-211) thousand corresponding to –1.5 (-4.9) percent of revenue · The COVID-19 pandemic continued to negatively affect especially the OEM sales of the Devices segment, whereas the Software segment continued its solid performance · Solid revenue growth in China · Regulatory approval

Nordea’s Board of Directors has decided on distribution of dividend

Nordea Bank AbpStock exchange release – Other information disclosed according to the rules of the Exchange18 February 2021 at 9.00 EET The Board of Directors of Nordea has today decided to distribute a dividend of EUR 0.07 per share to shareholders in accordance with the mandate received from the Annual General Meeting (“AGM”) in 2020. On 15 December 2020 the European Central Bank (“ECB”) issued an updated dividend recommendation to banks. The ECB in general expects dividends and share buy-backs to remain below 15% of the cumulated profit for 2019-20 and not to exceed 20bp of the

ContextVision’s annual sales match with previous record year

STOCKHOLM – February 18, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today reports its fourth quarter and full year 2020 results. Total sales 2020 reached 94.7 MSEK (95.3), which matches the record year 2019 if adjusted for currency exchange effect – a solid achievement much related to a strong start of the year. Total EBITDA ends at 25.5 MSEK and operating result reached 15.5 MSEK. Sales in the fourth quarter reached 23.5 MSEK (28.1), a 7% increase compared with the

Exel Composites continues the long-term incentive program for top management

EXEL COMPOSITES PLC      STOCK EXCHANGE RELEASE      18 FEBRUARY 2021 at 08:45 EETThe Board of Directors of Exel Composites Plc has decided on the continuation of the share-based long-term incentive program for the top management of Exel Composites. The 2021 performance-based plan is part of the share-based long-term incentive program published on 4 May 2017, which objectives are to align the interests of the management with those of the company’s shareholders and, thus, to promote shareholder value creation in the long term, to commit the management to achieving the strategic targets of

Kojamo plc’s Board of Directors decided to establish a long-term incentive plan

Kojamo plc Stock Exchange Release, 18 February 2021 at 8:45 a.m. EETKojamo plc’s Board of Directors decided to establish a long-term incentive plan Kojamo plc’s Board of Directors decided on 18 February 2021 to establish a new share-based incentive plan. The incentive plan consists of three performance periods (2021–2023, 2022–2024 and 2023–2025). The Board of Directors will determine the performance criteria for the performance periods, the targets to be set for each criterion, the target group and the level of possible rewards available for the key employees included in the target

New piece of the puzzle increases understanding of speciation

Speciation is important because it increases biodiversity. A thesis from the University of Gothenburg examines the speciation process in multiple marine species where different populations of the same species might evolve into two completely new species.When two populations of a species become isolated, their genes no longer intermix and over time, the two populations become increasingly different from each other. What is known as a reproduction barrier has then been formed because the two different populations no longer mate with each other even if they would meet again. For a long time,

Strong cash flow and financial position, despite Covid-19

[][] The fourth quarter: October – The full year 2020: January –December December · Net sales amounted to 269 · Net sales amounted toMSEK (333). 1,200 MSEK (1,221). · Order intake amounted to · Order intake amounted to230 MSEK (352). 933 MSEK (1,349). · Order backlog amounted to · Operating profit amounted1,087 MSEK (1,522). to 115 MSEK (140). · Operating profit amounted · Adjusted operating profitto 3 MSEK (38). amounted to 135 MSEK (140).[ ] · Adjusted operating

Panoro Energy – Update to Financial Calendar and Invitation to 4Q 2020 Trading and Financial update

Oslo, 18 February 2021 - Reference is made to the announcements dated 9 and 10 February 2021 regarding the acquisitions in Equatorial Guinea and Gabon, and the completed private placement of new shares. Due to the transformational nature of the acquisitions and the process of having a prospectus approved by the Norwegian Financial Supervisory Authority, the board of directors has decided not to publish a formal Q4 2020 financial report. However, on Thursday 25 February 2021, the Company will issue a trading and financial update which will include certain main line items for Q4. The Company

Adapteo Q4: High activity and geographic expansion

Adapteo Plc Regulatory press release 18 February 2021 at 7:30 a.m. CET October-December 2020 · Acquisition of the Dutch Cabin Group · Agreement to acquire Stord Innkvartering · Debt refinancing and share issue · Rental sales amounted to EUR 36.1 (35.1 in Q4 2019) million. In constant currencies, rental sales increased by 1%. · Net sales amounted to EUR 65.3 (49.6) million. In constant currencies, net sales increased by 29%. · Comparable EBITDA was EUR 24.2 (20.6) million. Comparable EBITDA margin was 37.0% (41.6%). · Operating cash flow before growth capex was EUR

QUARTERLY REPORT JANUARY TO DECEMBER 2020

STRONG CUSTOMER RESPONSE ON NEW SAAS BUSINESS MODELJanuary TO DECEMBER 2020 · Order intake* was 44.9 MSEK (62.7) · Order backlog* amounted to 35.2 MSEK (49.9) · Net Sales amounted to 53.8 MSEK (49.1) · Recurring Revenue amounted to 40.4 MSEK (27.1) · Usage Revenue as % of sales increased to 31% (16) · Gross Margin as % of sales increased to 66 % (61) · Adjusted EBITDA was -78.0 MSEK (-112.8) · Earnings per share amounted to -3.2 SEK (-7.4 SEK) October TO December 2020 · Order intake* amounted to 9.4 MSEK (17.0) · Net sales amounted to 9.7 MSEK (11.0) ·

Kojamo plc’s Financial Statements and Board of Directors’ Report 2020 have been published

Kojamo plc Stock Exchange Release, 18 February 2021 at 8:30 a.m. EETKojamo plc’s Financial Statements and Board of Directors’ Report 2020 have been published Kojamo plc’s Financial Statements and Board of Directors’ Report 2020 have been published today. The Financial Statements includes the consolidated financial statements, the parent company financial statements and the Auditor’s Report. In addition, the company has today published separate Corporate Governance Statement and Remuneration Report for the year 2020. The Financial Statements in Finnish are, for the first time,

Third consecutive quarter with increased subscriber growth rate

Readly presents a strong end to 2020 with an increased subscriber growth rate for the third consecutive quarter. Revenues amounted to SEK 98.6 million (73.5), representing growth of 34.2 per cent compared to the year before. The number of full-paying subscribers increased by 32.7 per cent to 369,764 (278,555) as per year-end. Gross profit increased by 42.7 per cent to SEK 33.6 million (23.5), corresponding to a gross margin of 34.1 per cent (32.0).“2020 was a strong year for Readly, and we saw continued good growth throughout the fourth quarter,” comments Maria Hedengren, CEO of Readly. “

Year-end report 2020

Record year in terms of sales and profitFourth quarter · Consolidated net sales increased by 2.2 per cent to SEK 95.6 million (93.5). · Operating profit (EBIT) increased by SEK 12.8 million to SEK 14.3 million (1.5). · Earnings per share after dilution amounted to SEK 0.47 (0.01). Full-year 2020, January – December 2020 · Consolidated net sales increased by 8.3 per cent to SEK 401.3 million (370.6). · Operating profit (EBIT) increased by SEK 28.4 million to SEK 60.4 million (32.0). · Earnings per share after dilution amounted to SEK 1.82 (0.87). · The Board of

Sinch AB (publ): Year-end report January – December 2020

Year-end report January – December 2020 October – December 2020 · Net sales increased by 95 percent to SEK 2,999.5 million (1,540.7). Organic growth was 43 percent. · Gross profit increased by 81 percent to SEK 795.7 million (439.9). Organic growth was 37 percent. · Adjusted EBITDA[1] increased by 63 percent to SEK 325.7 million (199.5). · Adjusted EBIT[2] amounted to SEK 303.7 million (185.7). · Profit after tax amounted to SEK 212.6 million (94.7). · Basic earnings per share were SEK 3.48 (1.77) and diluted earnings per share were SEK 3.37 (1.73).

Reminder: Invitation to Targovax’s Capital Markets Day 18 February 2021

Oslo, 18 February 2021 – Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual Capital Markets Day for investors, analysts and journalists today at 2:30 PM CET. The Capital Markets Day will feature presentations from executive management and Alexander Shousthari, Clinical Director Melanoma Services at Memorial Sloan Kettering Cancer Center, and will be webcast live and accessible at https://www.targovax.com/en/capital-markets-day-2021/Based on the strong clinical data that are now generated on ONCOS-102,

NOHO PARTNERS PLC FINANCIAL STATEMENTS RELEASE 1 JANUARY – 31 DECEMBER 2020: The year of COVID-19 caused an operating loss of MEUR 24 – following structural changes and a new financing agreement, the company prepares for a rebuilding phase

NoHo Partners Plc FINANCIAL STATEMENTS RELEASE 18 February 2021 at 8:15 a.m. NOHO PARTNERS PLC FINANCIAL STATEMENTS RELEASE 1 JANUARY – 31 DECEMBER 2020 The year of COVID-19 caused an operating loss of MEUR 24 – following structural changes and a new financing agreement, the company prepares for a rebuilding phase NoHo Partners operated in a restricted operating environment in all of the countries in which it operates during the last quarter of 2020. As a result of the acceleration of the pandemic, tightening restrictions on restaurants, weakened customer demand, complete halt

Qt Group Plc's annual report 2020 published

Qt Group Plc Stock exchange release 18 February 2021 at 8:01 (EET) Qt Group's Annual Report for the year 2020 has been published in Finnish and in English on the company's website http://investors.qt.io.The Annual Report contains the Board of Directors' report and the Auditors' report, the Financial Statements 2020, Corporate Governance Statement and Remuneration Report for Governing Bodies.A PDF file of the Annual Report 2020 is attached to this release.For more information, please contact:Jouni Lintunen, CFO, Qt Group Plc, tel. +358 9 8861 8040 Distribution:NASDAQ Helsinki

Nordic Nanovector ASA: Results for the Fourth Quarter and Full Year 2020

Oslo, Norway, 18 February 2020 Nordic Nanovector ASA (OSE: NANOV) announces its results for the fourth quarter and full year 2020. A live webcast presentation by Nordic Nanovector’s management team will take place today at 08.30 CET. A link to the webcast and the presentation is available from the company's homepage (www.nordicnanovector.com). Lars Nieba, interim Chief Executive Officer of Nordic Nanovector, commented: “The company has made significant efforts during 2020 to improve both the execution of PARADIGME and the chances of a viable regulatory filling outcome. The progress

BEWi – Invitation to presentation of results for fourth-quarter 2020

BEWi, a leading provider of packaging, components and insulation solutions, will announce its results for the fourth quarter of 2020 on Wednesday 24 February 2021. The results will be available from 07:00 am CET at the company's homepage, www.bewi.com and Oslo Stock Exchange's news site, www.newsweb.no. CEO Christian Bekken and CFO Marie Danielsson will present the results from 08:00 through a webinar hosted by Sparebank 1 Markets and can be accessed on the following link: https://attendee.gotowebinar.com/register/287597470345502219 

Year-End Report, 2020

Positive Topline Results from Pivotal Phase 3 NefIgArd Trial“On November 8, 2020, we announced positive topline readout of Part A of our Phase 3 pivotal trial, NefIgArd. The results were statistically significant and clinically relevant: proteinuria showed a 31% reduction versus baseline, a stronger effect than what was seen in the Phase 2b (27%), which is generally not expected when moving from Phase 2 to Phase 3. In addition, eGFR was stabilised in the treated patient population, which in the end is the true treatment goal. This potentially disease modifying effect is to our knowledge

There are no items matching the current filter
There are no more items matching the current filter
Back to top